The Patent Finder
NB

Nuvation Bio Inc.

First filing 2018
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Eight patents currently held, every record listed here

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in May 2039. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2039
Next term end
7
Patent families

When these terms end

Each bar runs from grant to computed term end. 2021 to 2042.
US 12,398,121 Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds May 14, 2039
US 11,192,900 Substituted 1,6-Dihydropyridinones and 1,2-Dihydroisoquinolinones as Bet Inhibitors Oct 30, 2039
US 12,208,141 Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds May 13, 2040
US 11,952,349 Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds Nov 12, 2040
US 11,826,430 Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds May 29, 2041
US 11,584,756 Heterocyclic Compounds as Bet Inhibitors Jun 4, 2041
US 11,834,458 Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds Mar 22, 2042
US 12,006,314 Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds May 2, 2042
202520292033203720412042
7 pending applications: term is not computable until grant.Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due May 28, 2027
    The maintenance fee for Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds (US 11,826,430) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
  • 1 fee due Jun 5, 2027
    The maintenance fee for Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds (US 11,834,458) comes due Jun 5, 2027. Unpaid by Dec 6, 2027, it lapses early.
  • 1 fee due Oct 9, 2027
    The maintenance fee for Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds (US 11,952,349) comes due Oct 9, 2027. Unpaid by Apr 10, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

The 5 largest of its 7 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 8 of 8

PatentTitleStatusExpiresConfidence
US 12,398,121Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds
In force
 · High confidence
In forceHigh confidence
US 11,192,900Substituted 1,6-Dihydropyridinones and 1,2-Dihydroisoquinolinones as Bet Inhibitors
In force
 · High confidence
In forceHigh confidence
US 12,208,141Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds
In force
 · High confidence
In forceHigh confidence
US 11,952,349Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds
In force
 · High confidence
In forceHigh confidence
US 11,826,430Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds
In force
 · High confidence
In forceHigh confidence
US 11,584,756Heterocyclic Compounds as Bet Inhibitors
In force
 · High confidence
In forceHigh confidence
US 11,834,458Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds
In force
 · High confidence
In forceHigh confidence
US 12,006,314Anti-Cancer Nuclear Hormone Receptor-Targeting Compounds
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 8: 10 patents ended · 7 applications pending · 23 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited